At Coherus, we put patients first.

We are dedicated to improving the availability of high-value, high-quality therapeutics. Our pipeline spans multiple therapeutic areas including oncology, immunology, and ophthalmology.

Our first product, UDENYCA^® (pegfilgrastim-cbqv), is an FDA-approved pegfilgrastim biosimilar.

With our expansion into immuno-oncology, toripalimab clinical trial results are expected over the next several years from a broad registrational clinical development program across multiple tumor types including cancers of the lung, esophagus, bladder, nasopharynx, stomach, breast, liver, and skin.

Our strategy is to invest cash flows from our commercial biosimilar business to build a fast-follower immuno-oncology franchise that will be synergistic with our proven commercial capabilities in oncology.